Unicycive Therapeutics Inc

자세한 내용은 Unicycive Therapeutics Inc 회사

Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.

회사 정보

종목 코드 UNCY

회사 이름Unicycive Therapeutics Inc

상장일Jun 17, 2021

CEODr. Shalabh Gupta, M.D.

직원 수22

유형Ordinary Share

회계 연도 종료Jun 17

주소4300 El Camino Real, Suite 210

도시LOS ALTOS

증권 거래소NASDAQ Capital Market Consolidated

국가United States of America

우편 번호94022

전화16503840642

웹사이트https://unicycive.com/

종목 코드 UNCY

상장일Jun 17, 2021

CEODr. Shalabh Gupta, M.D.

회사 임원

이름

이름/직위

직위

주식 보유

변동

Dr. Sandeep (Steve) Laumas, M.D.

Independent Director

10.58K

--

Dr. Pramod Gupta, Ph.D.

Executive Vice President - Pharmaceutical and Business Operations

4.18K

--

Dr. Shalabh Gupta, M.D.

Chairman of the Board, President, Chief Executive Officer, Founder

--

Mr. John Townsend

Chief Financial Officer

--

Mr. Doug Jermasek

Executive Vice President - Corporate Strategy

--

Dr. Gaurav Aggarwal, M.D.

Independent Director

--

Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Dr. Sandeep (Steve) Laumas, M.D.

Independent Director

10.58K

--

Dr. Pramod Gupta, Ph.D.

Executive Vice President - Pharmaceutical and Business Operations

4.18K

--

Dr. Shalabh Gupta, M.D.

Chairman of the Board, President, Chief Executive Officer, Founder

--

Mr. John Townsend

Chief Financial Officer

--

Mr. Doug Jermasek

Executive Vice President - Corporate Strategy

--

Dr. Gaurav Aggarwal, M.D.

Independent Director

--

수익 분석

데이터 없음

데이터 없음

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Tue, Aug 19

주주

주주 유형

주주

비율

Vivo Capital, LLC

6.44%

Octagon Capital Advisors LP

5.66%

Nantahala Capital Management, LLC

5.32%

Great Point Partners, LLC

4.51%

The Vanguard Group, Inc.

3.43%

기타

74.64%

주주

비율

Vivo Capital, LLC

6.44%

Octagon Capital Advisors LP

5.66%

Nantahala Capital Management, LLC

5.32%

Great Point Partners, LLC

4.51%

The Vanguard Group, Inc.

3.43%

기타

74.64%

주주 유형

주주

비율

Hedge Fund

24.67%

Venture Capital

12.61%

Individual Investor

4.93%

Investment Advisor

4.75%

Investment Advisor/Hedge Fund

0.73%

Research Firm

0.19%

기타

52.11%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

62

6.96M

54.51%

-655.75K

2025Q1

65

6.78M

64.49%

-1.12M

2024Q4

62

69.04M

66.51%

+542.97K

2024Q3

57

54.12M

55.45%

+17.71M

2024Q2

48

26.33M

50.66%

-3.75M

2024Q1

46

28.58M

99.15%

+4.37M

2023Q4

45

24.82M

96.62%

+1.55M

2023Q3

47

22.73M

96.91%

+9.25M

2023Q2

42

9.36M

61.47%

-512.55K

2023Q1

38

9.94M

65.95%

+1.31M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Vivo Capital, LLC

1.14M

8.9%

+140.00K

+14.04%

Mar 31, 2025

Octagon Capital Advisors LP

1.00M

7.83%

--

Mar 31, 2025

Nantahala Capital Management, LLC

939.20K

7.36%

-100.00K

-9.62%

Mar 31, 2025

Great Point Partners, LLC

1.10M

8.6%

--

Mar 31, 2025

The Vanguard Group, Inc.

121.24K

0.95%

+7.42K

+6.52%

Mar 31, 2025

Gupta (Shalabh K)

597.25K

4.68%

-100.00

-0.02%

Apr 30, 2025

Logos Global Management LP

507.89K

3.98%

--

Mar 31, 2025

Rosalind Advisors, Inc.

242.49K

1.9%

+242.49K

--

Apr 30, 2025

Armistice Capital LLC

97.60K

0.76%

--

Dec 31, 2023

Acuta Capital Partners, LLC

235.29K

1.84%

+4.99K

+2.17%

Mar 31, 2025

4.115USD

Unicycive Therapeutics Inc

4.115

개요

회사

금융